Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The single-tablet antiretroviral regimen includes Janssen’s darunavir plus Gilead’s cobicistat, emtricitabine and tenofovir alafenamide.
Charles Lyons, president and CEO of the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), analyzes data from a 2018 UNAIDS report.
The Impact of Hurricane Maria on HIV
Whites have a higher rate of successful HIV treatment.
Gene editing in monkeys creates SHIV-resistant immune cells.
AVR treatment halts brain damage and reduces damage.
Research found that healthcare providers could do better at preventing drug interactions.
Scientists tested the effects of the broadly neutralizing antibody PGT121 and the immune-stimulating agent GS-9620 in monkeys.
The Food and Drug Administration approves antibody treatment Trogarzo for multidrug-resistant HIV.
The newly approved single-tablet regimen contains the integrase inhibitor bictegravir plus emtricitabine and tenofovir alafenamide.
This long-acting drug is linked to undetectable viral loads in former prisoners with substance use disorders.
A star-shaped drug capsule could permit weekly dosing of HIV meds.
The risk for cervical cancer is lower for women living with HIV on treatment.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.